Hyderabad Oncology MoU Advances Precision Cancer Research
HYDERABAD, India, Feb. 16, 2026 — The University of Hyderabad and MNJ Institute of Oncology & Regional Cancer Centre...
Precision Oncology
Advertisement
Oncotelic Advances Late-Stage Oncology Pipeline into 2026
Agoura Hills, California — February 10, 2026: Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and...
Ensem Doses First China Patient in Global PI3Kα Trial
WALTHAM, Mass. & SHANGHAI, Feb. 2, 2026 — Ensem Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, announced that it...
XenoTherapeutics Completes Acquisition of Repare Therapeutics
Montreal, Canada | January 29, 2026 — Repare Therapeutics Inc., a clinical-stage precision oncology company, has completed its previously...
Scemblix® Gets Priority Access Under Ontario’s FAST Program
MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement...
Advertisements
Guardant Unveils New Multiomic Liquid Biopsy Insights at SABCS 2025
PALO ALTO, CA — December 5, 2025 — Guardant Health announced it will present 14 abstracts at the 2025...
FDA Accepts NDA for Nuvalent’s Zidesamtinib in ROS1+ NSCLC
Cambridge, Massachusetts — November 19, 2025 — Nuvalent, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Bio-Techne and Nucleai Advance AI Spatial Biology to Unlock Melanoma Biomarkers
MINNEAPOLIS, USA, and TEL AVIV, Israel, November 4, 2025 — Bio-Techne Corporation (NASDAQ: TECH) and Nucleai, an AI-driven precision-medicine...
Lantern Pharma Showcases AI Platforms to Accelerate Cancer Drug Discovery
Dallas, Texas, October 30, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present two cutting-edge AI-driven drug-development...
Tubulis Secures €344 M Series C to Accelerate ADC Clinical Growth
Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C...
Advertisement
